Results 1 to 10 of about 5,646 (108)

Efficient synthesis of α-galactosylceramide and its C-6 modified analogs [PDF]

Frontiers in Chemistry, 2022
The synthesis of α-galactosylceramide (KRN7000) and its C-6 modified analogs remains a challenge due to the difficult α-1,2-cis-glycosidic bond. A non-participating benzyl (Bn) protecting group has been commonly used to favor the α-glycosylation product.
Huiting Li, Hongzhao Mao, Chao Chen, Ying Xu, Shuai Meng, Tiantian Sun, Chengli Zong   +6 more
doaj   +2 more sources

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs [PDF]

Animal Diseases, 2022
Natural killer T (NKT) cells activated with the glycolipid ligand α-galactosylceramide (α-GalCer) stimulate a wide variety of immune cells that enhance vaccine-mediated immune responses. Several studies have used this approach to adjuvant inactivated and
Bianca L. Artiaga, Igor Morozov, Russell Ransburgh, Taeyong Kwon, Velmurugan Balaraman, Sabarish V. Indran, Darling Melany De Carvalho Madrid, Weihong Gu, Jamie Henningson, Wenjun Ma, Jürgen A. Richt, John P. Driver   +11 more
doaj   +2 more sources

Comparison of oseltamivir and α-galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus [PDF]

Frontiers in Veterinary Science, 2022
Influenza virus infections are a major cause of respiratory disease in humans. Neuraminidase inhibitors (NAIs) are the primary antiviral medication used to treat ongoing influenza infections.
Darling Melany de C. Madrid, Weihong Gu, Bianca L. Artiaga, Guan Yang, Julia Loeb, Julia Loeb, Ian K. Hawkins, William L. Castleman, John A. Lednicky, John A. Lednicky, Jürgen A. Richt, John P. Driver   +11 more
doaj   +2 more sources

Probiotic treatment with viable α‐galactosylceramide‐producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice [PDF]

Journal of Diabetes
Background We aimed to investigate whether alpha‐galactosylceramide (α‐GalCer)‐producing Bacteroides fragilis could induce natural killer T (NKT) cells in nonobese diabetic (NOD) mice and reduce their diabetes incidence.
Camilla H. F. Hansen, Danica Jozipovic, Line F. Zachariassen, Dennis S. Nielsen, Axel K. Hansen, Karsten Buschard   +5 more
doaj   +2 more sources

Donor Treg expansion by liposomal α‐galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft‐versus‐host disease [PDF]

Immunity, Inflammation and Disease, 2021
Background and Aim Chronic graft‐versus‐host disease (cGVHD) is a major cause of nonrelapse morbidity and mortality following hematopoietic stem cell transplantation (HSCT).
Hiroyuki Sugiura, Ken‐ichi Matsuoka, Takuya Fukumi, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Yusuke Meguri, Miki Iwamoto, Yasuhisa Sando, Makoto Nakamura, Tomohiro Toji, Yasuyuki Ishii, Yoshinobu Maeda   +12 more
doaj   +2 more sources

Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs [PDF]

Molecular Therapy: Methods & Clinical Development
Galsome-NEO is a glycolipid-adjuvanted mRNA lipid nanoparticle (LNP) cancer vaccine encoding neo-epitopes for evaluation in a phase 1 study in patients with non-small cell lung cancer.
Sofie Meulewaeter, Margo De Velder, Diethard Reckelbus, Kevin Mwangi, Thomas Ehouarne, Ilke Aernout, Yanou Engelen, Fellanza Halimi, Isis Van herteryck, Lobke De Bels, Valerie Redant, Louise De la Mane, Joline Ingels, Bo Coppens, Serge Van Calenbergh, Pieter Cornillie, Gabriële Holtappels, Benedicte Descamps, Daisy Vanrompay, Stefaan C. De Smedt, Wim Van den Broeck, Bart Vandekerckhove, Mathias Devreese, Rein Verbeke, Ine Lentacker   +24 more
doaj   +2 more sources

Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells [PDF]

Stem Cell Research & Therapy
Invariant natural killer T (iNKT) cells, upon activation, exhibit antitumor roles by bridging innate and acquired immunity. To overcome the challenges in producing iNKT cells from patients with cancer, we previously developed allogeneic human induced ...
Takahiro Aoki, Midori Kobayashi, Momoko Okoshi, Munechika Yamaguchi, Hiroko Okura, Satoko Sasaki, Yoshie Sasako, Sachiko Kira, Yun-Hsuan Chang, Nayuta Yakushiji-Kaminatsui, Jafar Sharif, Masashi Matsuda, Masahiro Kiuchi, Kiyoshi Hirahara, Motoko Y. Kimura, Shinichiro Motohashi, Haruhiko Koseki   +16 more
doaj   +2 more sources

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond [PDF]

Frontiers in Immunology, 2018
CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an ...
Lisa A. King, Roeland Lameris, Tanja D. de Gruijl, Hans J. van der Vliet, Hans J. van der Vliet   +4 more
doaj   +2 more sources

B Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases [PDF]

Frontiers in Immunology, 2019
Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in Mycobacterium tuberculosis as well as in some non-tuberculous mycobacteria (NTM), such as M. kansasii. M.
Bo-Eun Kwon, Jae-Hee Ahn, Eun-Kyoung Park, Hyunjin Jeong, Hyo-Ji Lee, Yu-Jin Jung, Sung Jae Shin, Hye-Sook Jeong, Jung Sik Yoo, EunKyoung Shin, Sang-Gu Yeo, Sun-Young Chang, Hyun-Jeong Ko   +12 more
doaj   +2 more sources

α-Galactosylceramide: a potent immunomodulator produced by gut microbes1 [PDF]

Journal of Lipid Research, 2019
Rotonya M. Carr
doaj   +2 more sources